GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InMed Pharmaceuticals Inc (NAS:INM) » Definitions » PS Ratio

INM (InMed Pharmaceuticals) PS Ratio : 0.32 (As of Mar. 14, 2025)


View and export this data going back to . Start your Free Trial

What is InMed Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, InMed Pharmaceuticals's share price is $2.82. InMed Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $8.73. Hence, InMed Pharmaceuticals's PS Ratio for today is 0.32.

The historical rank and industry rank for InMed Pharmaceuticals's PS Ratio or its related term are showing as below:

INM' s PS Ratio Range Over the Past 10 Years
Min: 0.18   Med: 0.57   Max: 69.21
Current: 0.3

During the past 13 years, InMed Pharmaceuticals's highest PS Ratio was 69.21. The lowest was 0.18. And the median was 0.57.

INM's PS Ratio is ranked better than
91.96% of 970 companies
in the Drug Manufacturers industry
Industry Median: 2.09 vs INM: 0.30

InMed Pharmaceuticals's Revenue per Sharefor the three months ended in Dec. 2024 was $1.57. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $8.73.

During the past 12 months, the average Revenue per Share Growth Rate of InMed Pharmaceuticals was -69.60% per year.

During the past 13 years, InMed Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was -54.20% per year. The lowest was -65.60% per year. And the median was -58.85% per year.

Back to Basics: PS Ratio


InMed Pharmaceuticals PS Ratio Historical Data

The historical data trend for InMed Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals PS Ratio Chart

InMed Pharmaceuticals Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 6.05 0.55 0.44

InMed Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.29 0.44 0.46 0.54

Competitive Comparison of InMed Pharmaceuticals's PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's PS Ratio falls into.



InMed Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

InMed Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=2.82/8.725
=0.32

InMed Pharmaceuticals's Share Price of today is $2.82.
InMed Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.73.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


InMed Pharmaceuticals  (NAS:INM) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


InMed Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals Business Description

Traded in Other Exchanges
Address
885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Executives
Mancini Alexandra Diane Janet officer: Sr VP, Clinical Reg Affairs C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Andrew Hull director C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Eric A Adams director, officer: President & CEO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Jonathan Tegge officer: Interim CFO 217 W. MAIN STREET, SOMERVILLE NJ 08876
Sarah Li officer: VP, Accounting and Controller 310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Bryan T Baldasare director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Brenda Edwards officer: Interim CFO 111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2
Janet P Grove director 510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5
Bruce Colwill officer: CFO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Shane Aaron Johnson officer: SVP & GM of BayMedica LLC 930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451
Adam D. Cutler director 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
William J Garner director 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010
Catherine Sazdanoff director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric C Hsu officer: Sr. VP, Pre-Clinical Res/Dev C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4